Chiesi Limited headquartered in Manchester, employs over 400 people. Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused group with over 85 years’ experience in the pharmaceutical sector operating in 30 countries, employing around 6,000 people. Chiesi’s Parma based Research and Development Centre coordinates the activities of six other centres in France, U.S.A, Canada, China, UK, and Sweden to promote its pre-clinical, clinical, and regulatory programmes. To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, Chiesi researches, develops and markets drugs in its three therapeutic areas: AIR (respiration, new-born to adult populations), RARE (rare and ultra-rare diseases) and CARE (special care and consumer-facing self-care). Chiesi, since 2019, is the world’s largest B Corp certified pharmaceutical group. The global B Corp movement promotes business as a force for good. The Group is committed to becoming carbon neutral by the end of 2035.
Further information: www.chiesi.uk.com